On September 29, 2021, the Attorney General of Canada sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 157) setting aside the decision...

On September 19, 2024, the Supreme Court of Canada granted Pharmascience leave to appeal a Federal Court of Appeal decision affirming a trial decision that upheld the validity of Janssen's patent relating to paliperidone palmitate

The Advisory Panel was established by the Canadian Agency for Drugs and Technologies in Health at the request of Health Canada.

Ian McMillan, Paul Blizzard and Leanne Young's article "Dealing with Intellectual Property during Bankruptcy and Insolvency"

Patricia Folkins, Reshika Dhir, and Coralee Ridder authored the article "At the Interfaces of Al, Chemistry and Patents - Opportunities and Challenges" published by Legal Industry Reviews.

The Internet has developed into an essential part of virtually every business, from online sales, to software as a service, to online marketing.

In view of the ongoing COVID-19 disruption, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed under the relevant legislation.

In view of the ongoing COVID-19 pandemic, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed...

In view of the ongoing COVID-19 disruption, the Canadian Intellectual Property Office (CIPO) has further extended patent, trademark, and industrial design deadlines fixed under the relevant...

Canada's federal government and common law provinces lack a general 'right of publicity' protecting personality rights as property. This article examines the limited statutory provisions covering personality rights in Canada, with Quebec as a notable exception under civil law jurisdiction.

On July 25, 2025, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2024/2025 for the Patented Medicines (Notice of Compliance) Regulations, Data Protection...

Canada's double patenting regime presents unique challenges for patent applicants, operating without the terminal disclaimer provisions available in the United States. This creates a complex landscape where Canadian applicants face heightened vulnerability to objections, requiring careful navigation with experienced legal guidance to successfully manage patent portfolios in this strict jurisdictional environment.

As we previously reported, the Ontario Court of Appeal affirmed the lower court's decision dismissing Apotex's claims against Eli Lilly under the Ontario and English Statutes of Monopolies, Trademarks Act...

Merck sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 224) affirming a Federal Court decision upholding Health Canada's refusal to add a patent relating to a formulation of Merck's KEYTRUDA...

On January 8, 2021, the Supreme Court of Canada denied leave to Janssen and Kennedy Trust (Docket No. 39099) with respect to the Federal Court

INVEGA SUSTENNA (paliperidone palmitate): Janssen v Pharmascience.

The world of digital marketing & advertising is fast-paced and always evolving to adopt the latest technology and capitalize on pop culture trends and new media channels.

In October 2020, the Pharmaceutical Advertising Advisory Board (PAAB) released an advisory addressing references to "no sub" or "no substitution" in advertising materials.

On February 1, 2023, the Minister of Health announced the appointment of Thomas J. Digby as the new Chairperson for the Patented Medicine Prices Review Board (PMPRB)...

Principals Ainslie Parsons and Noel Courage, along with expert international coauthors, recently contributed to an article in The Patent Lawyer Magazine examining how plant breeders and biotechs can protect...